A single-center study of 27 patients with relapsed core binding factor (CBF) AML has demonstrated that salvage hematopoietic cell transplantation (HCT) can result in two-year progression-free survival (PFS) of 80%. In this retrospective study, 27 consecutive patients with a median age of 39 years (range 3-67.5) with relapsed inv(16), t(16;16), or t(8;21) AML underwent allogeneic HCT between 2000-2013. Two-year cumulative incidences of post-HCT relapse/progression and non-relapse mortality were 8% and 12%, respectively. At a median follow up of 26 months, estimated two-year survival and PFS were both 80%. The researchers concluded that “HCT represents an important salvage therapy associated with extremely favorable outcomes for patients with relapsed CBF AML.”
Hobbs G, et al. Biol Blood Marrow Transplant (Full abstract only available to BBMT subscribers)